Skip to content
AMR Drug RepurposingSmart Screeningresearch prototype

Clindamycin Hydrochloride

FDA-approved product (capsule, oral), marketed as Cleocin, Cleocin Hydrochloride, Clindamycin Hydrochloride.

Registered studies
50+
Lab records
4
Pathogens at ≥40%
1 of 4

Chemical structure

Chemical structure of Clindamycin Hydrochloride
A drawing shows what the molecule is, not what it does.

Existing / approved use

Documented · FDA, WHO, ChEMBL

Approved for

  • Acne
  • Bacterial disease
  • Endometritis
  • Infection
  • Osteomyelitis
  • Pneumonia

Indications ChEMBL records as approved, from FDA and DailyMed labels. Label ↗

WHO therapeutic group
Antiinfectives for treatment of acne; Antibiotics; Lincosamides
Anti-infective classification
Classified as an existing antimicrobial.WHO ATC D10AF01; WHO ATC J01FF01; WHO ATC G01AA10

Repurposing investigation

Clindamycin Hydrochloride is already an antimicrobial, so it is not counted among the repurposing candidates. Its AI-predicted activity is shown below for reference.

AI-predicted activity

AI prediction · nothing measured
  • MRSA56.1% AI-predicted activityAt or above the ≥40% mark this site uses to surface candidates.
  • E. coli13.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • K. pneumoniae11.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates.
  • M. tuberculosis4.2% AI-predicted activityBelow the ≥40% mark this site uses to surface candidates. This medicine was in the model's training data, so this is recall, not a new prediction.

A model’s estimate of laboratory activity against each pathogen species. It is not clinical effectiveness.

Evidence

Clinical and experimental

Documented evidence

Clinical

50+registered studies name this medicine, for any condition. The registry search keeps the first 50, so there may be more. See them below.

Experimental

  • M. tuberculosis: measured active in 0 of 4 lab records
Open Clindamycin Hydrochloride in ChEMBL Registered studies below
Show the 4 laboratory records, with sources

Loading records…

“Active” means the measured value reached this project’s laboratory cutoff (10 µM or stronger). A laboratory result does not show an effect in patients.

Docking

Computational · nothing measured

Dihydrofolate reductase ↗ (E. coli)

-6.1 kcal/mol

0better fit →-12

KPC-2 carbapenemase ↗ (K. pneumoniae)

-7.1 kcal/mol

0better fit →-12

Enoyl-ACP reductase (InhA) ↗ (M. tuberculosis)

-7.2 kcal/mol

0better fit →-12

Dihydrofolate reductase ↗ (MRSA)

-6.5 kcal/mol

0better fit →-12

AutoDock Vina, one experimentally solved protein per pathogen. This project’s screening target is -7.0 kcal/mol, its own mark rather than a universal cutoff. A docking score is a structural hypothesis, not proof of binding, and requires experimental validation.

Other medicines to investigate

AI prediction · nothing measured

Other repurposing candidates: approved medicines besides Clindamycin Hydrochloride with AI-predicted activity ≥40% against the chosen pathogen, leaving out existing antimicrobials. They are computational candidates for further investigation, not alternatives and not recommendations.

Sorted by AI-predicted activity, high to low. The order is not a ranking of which medicine is better.

Registered studies

A registration describes a study; it does not establish a positive result.

  • A Clinical Study Evaluating the Safety and Efficacy of IDP-110 in Patients With Acne Vulgaris

    NCT00664248 · start 2006-10

    Registered record
    Registry ID
    NCT00664248
    Conditions
    Acne Vulgaris
    Interventions
    IDP-110; Clindamycin; Benzoyl peroxide; Vehicle
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Completed
    Start
    2006-10
    Completion
    Not recorded
    Enrolment
    1,414

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionAcne Vulgaris
    InterventionIDP-110; Clindamycin; Benzoyl peroxide; Vehicle
    PhasePhase 3
    Registry statusCompleted

  • Skin Toxicity Treatment in Metastatic Colorectal Cancer (mCRC) Patients Receiving Panitumumab + Irinotecan-based Therapy

    NCT00332163 · start 2006-04

    Registered record
    Registry ID
    NCT00332163
    Conditions
    Metastatic Colorectal Cancer; Skin Rash; Skin Toxicities; Colon Cancer; Colorectal Cancer
    Interventions
    Panitumumab; Irinotecan; FOLFIRI; Pre-emptive Skin Treatment; Reactive Skin Treatment
    Study type
    INTERVENTIONAL
    Phase
    Phase 2
    Registry status
    Completed
    Start
    2006-04
    Completion
    2008-09
    Enrolment
    95

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionMetastatic Colorectal Cancer; Skin Rash; Skin Toxicities; Colon Cancer +1 more
    InterventionPanitumumab; Irinotecan; FOLFIRI; Pre-emptive Skin Treatment +1 more
    PhasePhase 2
    Registry statusCompleted

  • To Compare Intravitreal Clindamycin & Dexamethasone With Classic Treatment of Toxoplasmic Retinochoroiditis

    NCT00372294 · start 2005-07

    Registered record
    Registry ID
    NCT00372294
    Conditions
    Chorioretinitis
    Interventions
    pyrimethamine-sulfadiazine + prednisolone; Clindamycin+Dexamethasone
    Study type
    INTERVENTIONAL
    Phase
    Phase 3
    Registry status
    Unknown
    Start
    2005-07
    Completion
    2008-11
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionChorioretinitis
    Interventionpyrimethamine-sulfadiazine + prednisolone; Clindamycin+Dexamethasone
    PhasePhase 3
    Registry statusUnknown

  • Antibiotics for Postpartum Third and Fourth Degree Perineal Tear Repairs

    NCT00186082 · start 2003-09

    Registered record
    Registry ID
    NCT00186082
    Conditions
    Pregnancy Complications, Infectious
    Interventions
    Cefotetan or Cefoxitin vs placebo
    Study type
    INTERVENTIONAL
    Phase
    Not applicable
    Registry status
    Completed
    Start
    2003-09
    Completion
    2008-06
    Enrolment
    147

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionPregnancy Complications, Infectious
    InterventionCefotetan or Cefoxitin vs placebo
    PhaseNot applicable
    Registry statusCompleted

  • Prophylaxis of Acute Post-Traumatic Bacterial Endophthalmitis

    NCT00398658 · start 2002-03

    Registered record
    Registry ID
    NCT00398658
    Conditions
    Endophthalmitis; Prophylaxy of Post Traumatic Endophthalmitis; Bacterial Endophthalmitis
    Interventions
    gentamycin and clindamycin
    Study type
    INTERVENTIONAL
    Phase
    Phase 4
    Registry status
    Completed
    Start
    2002-03
    Completion
    2004-12
    Enrolment
    Not recorded

    As stored from ClinicalTrials.gov. Registration describes a study; it does not mean the study worked.

    ConditionEndophthalmitis; Prophylaxy of Post Traumatic Endophthalmitis; Bacterial Endophthalmitis
    Interventiongentamycin and clindamycin
    PhasePhase 4
    Registry statusCompleted